[1]
|
Plueschke, K., Mc Gettigan, P., Pacurariu, A., et al. (2018) EU-Funded Initiatives for Real World Evidence: Descriptive Analysis of Their Characteristics and Relevance for Regulatory Decision-Making. BMJ Open, 8, e021864.
https://doi.org/10.1136/bmjopen-2018-021864
|
[2]
|
Reynolds, C., Masters, E., TBlack-Shinn, J., et al. (2018) Real World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. Journal of Clinical Medicine, 7, 129. https://doi.org/10.3390/jcm7060129
|
[3]
|
Mangat, P.K., Halabi, S., Bruinooge, S.S., et al. (2018) Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology, 18, 1-14. https://doi.org/10.1200/PO.18.00122
|
[4]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[5]
|
Gao, S.J., Corso, C.D., Wang, E.H., et al. (2017) Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12, 314-322.
https://doi.org/10.1016/j.jtho.2016.09.122
|
[6]
|
Klapper, J. and D’Amico, T.A. (2015) VATS versus Open Surgery for Lung Cancer Resection: Moving toward a Minimally Invasive Approach. Journal of the National Comprehensive Cancer Network, 13, 162-164.
https://doi.org/10.6004/jnccn.2015.0023
|
[7]
|
Huang, J., Xu, X., Chen, H., et al. (2013) Feasibility of Complete Video Assisted Thoracoscopic Surgery Following Neoadjuvant Therapy for Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Disease, 5, S267-S273.
|
[8]
|
Zhao, W., Chen, T., Ji, C., et al. (2021) Feasibility of Surgical Resection after Induction Epidermal Growth Factor Receptor-Tyro-Sine Kinase Inhibitor Therapy for n2 Lung Adenocar-cinomas. The Annals of Thoracic Surgery, 111, 290-295. https://doi.org/10.1016/j.athoracsur.2020.04.133
|
[9]
|
Zhong, W.Z., Chen, K.N., Chen, C., et al. (2019) Erlotinib versus Gemcitabine plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. Journal of Clinical Oncology, 37, 2235-2245. https://doi.org/10.1200/JCO.19.00075
|
[10]
|
Corey, J.L., Shirish, M.G., Hossein, B., et al. (2019) OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed with or without Pembrolizumab for nonsqua-mousNSCLC. Journal of Thoracic Oncology, 14, S216.
https://doi.org/10.1016/j.jtho.2019.08.426
|
[11]
|
Cascone, T., William, W.J., Weissferdt, A., et al. (2021) Neoadju-vantnivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514.
https://doi.org/10.1038/s41591-020-01224-2
|
[12]
|
Blumenthal, G.M., Bunn, P.A., Chaft, J.E., et al. (2018) Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 13, 1818-1831. https://doi.org/10.1016/j.jtho.2018.09.017
|
[13]
|
Kelly, K., Altorki, N.K., Eberhardt, W.E., et al. (2015) Adjuvant Erlotinib versus Placebo in Patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 33, 4007-4014. https://doi.org/10.1200/JCO.2015.61.8918
|
[14]
|
Zhong, W.Z., Wang, Q., Mao, W.M., et al. (2018) Gefitinib versus Vinorelbine plus Cisplatin as Adjuvant Treatment for Stage Ⅱ-ⅢA(N1N2) EGFR-Mutant NSCLC (ADJUVANT/CTONG1104): A Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 19, 139-148. https://doi.org/10.1016/S1470-2045(17)30729-5
|
[15]
|
Forde, P.M., Chaft, J.E. and Pardoll, D.M. (2018) Neoadju-vant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medicine, 378, 1976-1986. https://doi.org/10.1056/NEJMoa1716078
|
[16]
|
Antonia, S.J., Villegas, A., Daniel, D., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage Ⅲ NSCLC. The New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/NEJMoa1809697
|
[17]
|
Martin, J., Ginsberg, R.J., Venkatraman, E.S., et al. (2002) Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer. Journal of Clinical On-cology, 20, 1989-1995.
https://doi.org/10.1200/JCO.2002.08.092
|
[18]
|
Wu, Y.L., Zhang, L., Kim, D.W., et al. (2018) Phase Ib/II Study of Capmatinib (INC280) plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Pa-tients with EGFR-Mutated, MET Factor-Dysregulated Non Small Cell Lung Cancer. Journal of Clinical Oncology, 36, 3101-3109.
https://doi.org/10.1200/JCO.2018.77.7326
|
[19]
|
NSCLC Meta-Analysis Collaborative Group (2014) Preoperative Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Participant Data. The Lancet, 383, 1561-1571.
https://doi.org/10.1016/S0140-6736(13)62159-5
|
[20]
|
Cascone, T., Hamdi, H., Zhang, F., et al. (2018) Superior Ef-ficacy of Neoadjuvant Compared to Adjuvant Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Research, 78, 1719.
https://doi.org/10.1158/1538-7445.AM2018-1719
|